Therapie von menopausalen Symptomenbei Patientinnen mit Krebserkrankungen

Eine Hormonersatztherapie (HRT) ist für viele Frauen in der Peri- und Postmenopause eine effektive Behandlungsmethode ihrer menopausalen Symptome. Allerdings können endokrine Interventionen das Risiko für verschiedene Krebserkrankungen beeinflussen. Klimakterische Beschwerden können jedoch auch als Nebenwirkung einer Krebstherapie auftreten. Bei solchen Patientinnen muss die Therapie menopausaler Symptome daher differenziert betrachtet werden.

Schlüsselwörter

Klimakterische Beschwerden - vasomotorische Symptome - Menopause - HRT - nichthormonale Therapien - Krebspatientinnen - onkologische Sicherheit

• Literatur

• 1 National Institute for Health and Clinical Excellence. Menopause: Clinical guideline. Methods, evidence and recommendations. [Appendices I–K]. UK: National Institute for Health and Clinical Excellence; 2015
• 2 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V. (DGGG) (federführend). S3-Leitlinie Peri- und Postmenopause – Diagnostik und Interventionen: AWMF-Registernummer: 015–062. 2020
• 3 Křížová L, Dadáková K, Kašparovská J. et al. Isoflavones. Molecules 2019; 24: 1076
• 4 Fritz H, Seely D, Flower G. et al. Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS One 2013; 8: e81968
• 5 Fritz H, Seely D, McGowan J. et al. Black cohosh and breast cancer: a systematic review. Integr Cancer Ther 2014; 13: 12-29
• 6 Beer A-M, Neff A. Differentiated evaluation of extract-specific evidence on Cimicifuga racemosa’s efficacy and safety for climacteric complaints. Evid Based Complement Alternat Med 2013; 2013: 860602
• 7 Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012; (09) CD007244
• 8 Franco OH, Chowdhury R, Troup J. et al. Use of plant-based therapies and menopausal symptoms: A systematic review and meta-analysis. JAMA 2016; 315: 2554-2563
• 9 You M-K, Kim H-J, Kook JH. et al. St. John’s Wort regulates proliferation and apoptosis in MCF-7 human breast cancer cells by inhibiting AMPK/mTOR and activating the mitochondrial pathway. Int J Mol Sci 2018; 19: 966
• 10 Rada G, Capurro D, Pantoja T. et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010; (09) CD004923
• 11 van Driel CM, Stuursma A, Schroevers MJ. et al. Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. BrJ Obstet Gyneaecol 2019; 126: 330-339
• 12 Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Langversion 4.1. Wöckel A. Germering/München: Zuckschwerdt; 2018
• 13 Manson JE, Chlebowski RT, Stefanick ML. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353-1368
• 14 Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394: 1159-1168
• 15 Kenemans P, Bundred NJ, Foidart J-M. et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135-146
• 16 Holmberg L, Iversen O-E, Rudenstam CM. et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008; 100: 475-482
• 17 Fahlén M, Fornander T, Johansson H. et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013; 49: 52-59
• 18 Donders G, Neven P, Moegele M. et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 2014; 145: 371-379
• 19 Vargiu V, Amar ID, Rosati A. et al. Hormone replacement therapy and cervical cancer: a systematic review of the literature. Climacteric 2021; 24: 120-127
• 20 Beral V, Gaitskell K, Hermon C. et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015; 385: 1835-1842
• 21 Eeles RA, Morden JP, Gore M. et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: Results of the AHT randomized trial. J Clin Oncol 2015; 33: 4138-4144
• 22 Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors – Review of the literature. Pathol Oncol Res 2020; 26: 63-78
• 23 Mørch LS, Lidegaard Ø, Keiding N. et al. The influence of hormone therapies on colon and rectal cancer. Eur J Epidemiol 2016; 31: 481-489
• 24 Jang Y-C, Huang H-L, Leung CY. Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis. BMC Cancer 2019; 19: 1199
• 25 Denschlag D, Egerer G. Sarcoma of the uterus: Guideline of the DGGG and OEGGG (S2k level, AWMF register number 015/074, February 2019) = Uterine Sarkome : Leitlinie der DGGG und OEGGG (S2k-Level, AWMF-Register-Nummer 015/074, Februar 2019). Geburtshilfe Frauenheilkd 2019; 79: 1043-1060